In a pemphigus patient receiving systemic steroids and cyclophosphamide who develops sepsis, should the steroids be continued (or adjusted) and should cyclophosphamide be stopped?

Management of Immunosuppression in Pemphigus Patients with Sepsis

In a pemphigus patient on steroids and cyclophosphamide who develops sepsis, you should immediately stop cyclophosphamide but continue steroids at stress doses (hydrocortisone 200-300 mg/day or equivalent). This approach prioritizes survival from the acute septic episode while preventing adrenal crisis from steroid withdrawal.

Cyclophosphamide: Stop Immediately

Cyclophosphamide must be discontinued when serious infection develops. The FDA label explicitly states that "cyclophosphamide treatment may not be indicated, or should be interrupted, or the dose reduced, in patients who have or who develop a serious infection" 1. The drug causes severe immunosuppression leading to "serious and sometimes fatal infections, including sepsis and septic shock" 1.

Key Rationale for Stopping Cyclophosphamide:

• Direct causation of sepsis: Cyclophosphamide-induced myelosuppression and immunosuppression can directly cause or worsen sepsis
• Mortality risk: The drug label warns of fatal infections as a known complication 1
• Reversibility: Unlike steroids, cyclophosphamide can be safely interrupted without immediate life-threatening consequences
• Pemphigus control: Even in the original DCP regimen studies, mortality rates of 2-4% were reported during treatment, often infection-related 2

Common Pitfall to Avoid:

Do not continue cyclophosphamide thinking you need to control the pemphigus during sepsis. The immediate mortality risk from worsening sepsis far outweighs any risk of pemphigus flare during the acute infection period.

Corticosteroids: Continue at Stress Doses

Steroids should be continued and potentially increased to stress doses during sepsis. This recommendation is supported by two critical considerations:

1. Prevention of Adrenal Crisis

Patients on chronic corticosteroids (as used in pemphigus treatment) develop hypothalamic-pituitary-adrenal axis suppression. Abrupt discontinuation during the physiologic stress of sepsis can precipitate life-threatening adrenal crisis. The pemphigus guidelines note that "pituitary-adrenal suppression in 55% of patients" occurs with DCP therapy 2.

2. Potential Mortality Benefit in Sepsis

The 2018 BMJ sepsis guideline provides a weak recommendation for corticosteroids in sepsis, noting that "corticosteroids may reduce the risk of death by a small amount" 3. The guideline states that "fully informed patients who value avoiding death over quality of life and function would likely choose corticosteroids" 3.

Practical Steroid Management:

Dosing approach:

• If patient was on moderate-high dose steroids for pemphigus (e.g., prednisolone 0.5-1 mg/kg/day): Continue current dose or switch to hydrocortisone 200-300 mg/day IV (divided or continuous infusion) 3
• If patient was on low-dose maintenance steroids: Increase to stress doses (hydrocortisone 200-300 mg/day equivalent) 3
• Typical hydrocortisone regimen: 50 mg IV every 6 hours or continuous infusion after 50-100 mg bolus 3

Duration:

• Continue stress doses for 7-14 days or until sepsis resolves and patient is clinically improving 3
• Monitor carefully for rebound inflammation when tapering 3

Monitoring:

• Hyperglycemia (common, requires insulin management)
• Hypernatremia and hypokalemia
• Signs of adrenal insufficiency if doses are reduced too quickly 3

After Sepsis Resolution

Restarting Cyclophosphamide:

Once the infection has completely resolved and blood counts have recovered (neutrophils >1,500/mm³, platelets >50,000/mm³), cyclophosphamide can be cautiously reintroduced if still needed for pemphigus control 1. However, given the high relapse-free rates with cyclophosphamide (70% remained off therapy for average 7 years in one study 4), consider whether the patient still requires it.

Steroid Tapering:

After sepsis resolution, taper steroids gradually back to the dose needed for pemphigus control. The British guidelines recommend 25% reductions every 2 weeks when above 20 mg prednisolone equivalent, then 5 mg reductions every 4 weeks below 20 mg 2, 5. Monitor for both pemphigus relapse and signs of adrenal insufficiency.

Alternative Consideration:

If the patient requires ongoing immunosuppression after recovering from sepsis, consider transitioning to rituximab rather than restarting cyclophosphamide, as it has superior efficacy with potentially lower infection risk in the long term 2.

Critical Caveats

Infection source control is paramount: No immunosuppression management strategy will succeed without appropriate antibiotics, source control, and supportive care for sepsis.

G-CSF consideration: If neutropenia is present or develops, G-CSF should be administered to reduce neutropenia complications 1.

Individual severity matters: Patients with septic shock (requiring vasopressors) have the greatest absolute mortality benefit from corticosteroids 3, making steroid continuation even more critical in this subgroup.